|Traded as||BSE: 532296
|Industry||Pharmaceuticals, Drugs & Healthcare|
|Headquarters||Mumbai, Maharashtra, India|
|Key people||Glenn Saldanha, MD & CEO |
|Products||Medicines and Vaccines|
|Revenue||1031.10 crore (US$170 million) (2009–2010) |
|Subsidiaries||Glenmark Generics Ltd|
Glenmark Pharmaceuticals is a pharmaceutical company headquartered in Mumbai, India.  It manufactures and markets generic formulation products and active pharmaceutical ingredients (API), both in the domestic and international markets. In the formulation business, its business spans segments such as Dermatology, Internal Medicine, Paediatrics, Gynaecology, ENT and Diabetes.
It has four manufacturing facilities for formulations and additional three facilities for APIs. These manufacturing facilities are located in the states of Maharashtra, Goa, Himachal Pradesh and Gujarat in India.
It operates in 95 countries through its subsidiaries, Glenmark Pharmaceuticals USA, Glenmark Pharmaceuticals UK. Glenmark Pharmaceuticals SA. 
- "If I were FM | Glenn Saldanha, managing director and CEO, Glenmark Pharmaceuticals – Economy and Politics". livemint.com. 2009-07-01. Retrieved 2010-09-30.
- "BSE Plus". Bseindia.com. Retrieved 2010-09-30.
- "Glenmark Pharmaceuticals Ltd. (2529483): Stock Quote & Company Profile – BusinessWeek". Investing.businessweek.com. Retrieved 2010-09-30.
- "Glenmark Pharmaceuticals | TopNews". Topnews.in. Retrieved 2010-09-30.
- "about Glenmark Pharmaceuticals". www.ibef.org. Retrieved 2010-09-30.
- "Glenmark Pharmaceuticals acquires Bouwer Bartlett, South Africa". domain-b.com. 2005-12-26. Retrieved 2010-09-30.